2010 - Member of Academia Europaea
His primary scientific interests are in Arthritis, Internal medicine, Immunology, Interleukin 6 and Macrophage activation syndrome. His Arthritis study incorporates themes from Interleukin, Methotrexate, Rheumatoid arthritis and Intensive care medicine. His Internal medicine research integrates issues from Gastroenterology and Endocrinology.
His work in the fields of Immunology, such as Tumor necrosis factor alpha, Perforin and Cellular immunity, overlaps with other areas such as Peripheral blood mononuclear cell. His Interleukin 6 study is focused on Cytokine in general. He combines subjects such as Chemokine, Interferon gamma, CXCL9 and Biologic therapies with his study of Macrophage activation syndrome.
Fabrizio De Benedetti focuses on Internal medicine, Arthritis, Immunology, Rheumatology and Tocilizumab. His study looks at the intersection of Internal medicine and topics like Gastroenterology with Absolute neutrophil count. In the field of Arthritis, his study on Macrophage activation syndrome overlaps with subjects such as In patient.
His is involved in several facets of Immunology study, as is seen by his studies on Interleukin 6, Inflammation, Proinflammatory cytokine, Immune system and Cytokine. His Rheumatology research is multidisciplinary, incorporating elements of MEDLINE, Erythrocyte sedimentation rate, Physical therapy, Etanercept and Pediatrics. The study incorporates disciplines such as Randomized controlled trial and Neutropenia in addition to Tocilizumab.
The scientist’s investigation covers issues in Internal medicine, Arthritis, Immunology, Anakinra and Tocilizumab. His Internal medicine study frequently involves adjacent topics like Gastroenterology. His study of Macrophage activation syndrome is a part of Arthritis.
His research investigates the link between Immunology and topics such as Hemophagocytic lymphohistiocytosis that cross with problems in Ex vivo. Fabrizio De Benedetti has researched Anakinra in several fields, including First episode, Acute pericarditis, Pericarditis and Discontinuation. Fabrizio De Benedetti works mostly in the field of Tocilizumab, limiting it down to concerns involving Randomized controlled trial and, occasionally, Quality of life.
His primary areas of investigation include Internal medicine, Arthritis, Immunology, Cytokine and Inflammation. Internal medicine and Gastroenterology are commonly linked in his work. His work deals with themes such as Anakinra, Tocilizumab, Disease and Rheumatology, which intersect with Arthritis.
His work on Immune system, Immune dysregulation, Hypogammaglobulinemia and B cell as part of general Immunology study is frequently connected to Adenosine Deaminase 2 Deficiency, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His research integrates issues of Cytopenia, Rash and Cell biology in his study of Inflammation. As a part of the same scientific family, Fabrizio De Benedetti mostly works in the field of Interleukin 18, focusing on Immunopathology and, on occasion, Interleukin 6.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.
Jurgen Sota;Antonella Insalaco;Rolando Cimaz;Maria Alessio.
Frontiers in Pharmacology (2019)
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Fabrizio De Benedetti;Hermine I. Brunner;Nicolino Ruperto;Andrew Kenwright.
The New England Journal of Medicine (2012)
Interleukin 6 is required for the development of collagen-induced arthritis.
Tonino Alonzi;Elena Fattori;Domenico Lazzaro;Patrizia Costa.
Journal of Experimental Medicine (1998)
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli;Francesca Serena Minoia;Sergio Davi;Anna Carin Horne.
Arthritis & Rheumatism (2016)
On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Lauren A Henderson;Scott W Canna;Grant S Schulert;Stefano Volpi.
Arthritis & Rheumatism (2020)
Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis
Fabrizio de Benedetti;Margherita Massa;Piera Robbioni;Angelo Ravelli.
Arthritis & Rheumatism (1991)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
Angelo Ravelli;Francesca Minoia;Sergio Davì;Annacarin Horne.
Annals of the Rheumatic Diseases (2016)
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis.
Rachelle Donn;Zaynab Alourfi;Fabrizio De Benedetti;Cristina Meazza.
Arthritis & Rheumatism (2002)
Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system.
Fabrizio De Benedetti;Nadia Rucci;Andrea Del Fattore;Barbara Peruzzi.
Arthritis & Rheumatism (2006)
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
Fabrizio De Benedetti;Marco Gattorno;Jordi Anton;Eldad Ben-Chetrit.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: